Glycans Meet Sphingolipids: Rational Structure-Based Design of a New Generation of Sphingosine Kinase Inhibitors

<none>

Programme Social programme Plenary speakers Keynote speakers 1st EuroCarb Young Researcher (ECYR) Workshop CarboMet Workshop Mini symposium: Glycobiology at the LUMC and beyond Favourites/Agenda

Social programme

Plenary speakers

Keynote speakers

1st EuroCarb Young Researcher (ECYR) Workshop

CarboMet Workshop

Mini symposium: Glycobiology at the LUMC and beyond

Favourites/Agenda

Photos

Venue & Travel Venue Accommodation City of Leiden Travel directions

Venue

Accommodation

City of Leiden

Travel directions

Committees

Home

Glycans Meet Sphingolipids: Rational Structure-Based Design of a New Generation of Sphingosine Kinase Inhibitors

Federica Compostella 2 , Athanasios Athanasios Papakyriakou 3 , Laura Morelli 2 , Elisa Puliti 4 , Francesca Cencetti 4 , Paola Bruni 4 , Barbara Richichi 1

1 University of Florence, Department of Chemistry 'Ugo Schiff', Sesto Fiorentino, Italy, 2 University of Milan, Department of Medical Biotechnology and Translational Medicine, Milano, Italy, 3 Institute of Biosciences & Applications, NCSR “Demokritos”, Athenes, Greece, 4 Department of Experimental and Clinical Biomedical Sciences, University of Florence, Firenze, Italy

Sphingosine kinases, SK1 and SK2, are enzymes localized respectively in the cytosol and in intracellular compartments, which catalyze the production of sphingosine-1-phosphate (S1P) in an ATP-dependent manner. Solid experimental evidences implicate the S1P axis in different pathological conditions (e.g. cancer, inflammatory disease, fibrosis), and aberrant S1P levels and/or SKs expression have been associated with diseases progression [1]. In this regards, the manipulation of S1P axis using chemical tools has been exploited either looking at the inhibition of SK activity and by the modulation of S1P receptors signaling. Specifically, a wide number of SK1 inhibitors have been developed to date. However, most of them are still limited by low potency and/or specificity among SK subtypes, indicating the need for new and more efficient SK1 inhibitors.

In this framework, we report here on an original approach for the rational structure-based design of SK1 inhibitors. It relies on the integration of the information coming from the SK1-co-crystal structure of known validated inhibitors into pharmacophoric models. This approach aims at the development of better ‘molecular fitting’ inhibitors by using glycans as an anchoring polar head allowing to hold inhibitors at the J-shaped hydrophobic binding pocket of SK [2]. In particular, in this communication we report on the rational structure-based design and stereoselective synthesis of glycan-containing PF543 analogues (Figure 1), one of the most potent SK1 inhibitors reported so far. Moreover, a preliminary evaluation of the role of the new synthesized SK inhibitors in TGFβ-induced fibrosis of murine myoblasts to confirm the rationale of the proposed approach is described.

Figure 1

Pyne S, Adams DR, Pyne NJ. Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances. Prog Lipid Res. 2016, 62:93-106

Wang J, Knapp S, Pyne NJ, Pyne S, Elkins JM Crystal Structure of Sphingosine Kinase 1 with PF-543. ACS Med. Chem. Letters 2014, 5, 1329-1333

Contact eurocarb@eurocarb2019.com for general questions about EUROCARB2019, or codee@eurocarb2019.com for scientific questions.

Leiden University / Leiden Institute of Chemistry lic.leidenuniv.nl

European Carbohydrate Organisation

Congress by Design www.congressbydesign.com